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Abstract
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An assay was developed for phosphofructokinase-1 (PFK-1) using capillary electrophoresis (CE).
In the glycolytic pathway, this enzyme catalyzes the rate-limiting step from fructose-6-phosphate
and magnesium-bound adenosine triphosphate (Mg-ATP) to fructose-1,6-bisphosphate and
magnesium-bound adenosine diphosphate (Mg-ADP). This enzyme has recently become a
research target because of the importance of glycolysis in cancer and obesity. The CE assay for
PFK-1 is based on the separation and detection by UV absorbance at 260 nm of Mg-ATP and MgADP. The separation was enhanced by addition of Mg2+ to the separation buffer. Inhibition
studies of PFK-1 by aurintricarboxylic acid and palmitoyl coenzyme A were also performed. An
IC50 value was determined for aurintricarboxylic acid, and this value matched values in the
literature obtained using coupled spectrophotometric assays. This assay for PFK-1 directly
monitors the enzyme-catalyzed reaction, and the CE separation reduces the potential of spectral
interference by inhibitors.
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INTRODUCTION
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Phosphofructokinase-1 (PFK-1) is an allosteric enzyme that catalyzes the ATP-dependent
phosphorylation of fructose 6-phosphate (F6P) to fructose 1,6-bisphosphate (F1,6P) as
shown in Scheme 1. This reaction is one of the principal regulatory steps in glycolysis [1],
and as such PFK-1 is a homotetramer, which allows the activity of the enzyme to be
controlled allosterically by the cellular energy level or ATP/AMP ratio [1]. Citrate and ATP
act as feedback inhibitors of PFK-1, while AMP, ADP and fructose 2,6-bisphosphate
activate the enzyme [2]. The mammalian form of the enzyme has three different isozymes:
M for muscle, L for liver and P for platelets (also called PFK-C) [2; 3]. While most PFK-1
research has focused on its regulatory properties [1; 2; 3], very little effort has been put into
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developing inhibitors of the enzyme. This is unfortunate given that there are potential
medical applications for the inhibition of PFK-1.
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PFK-1 is a potential target for the treatment of obesity and infectious disease. A recent
report by Getty-Kaushik et al. [4] found that mice deficient in the M isozyme of PFK-1 had
significantly decreased fat stores. This suggests that inhibition of muscle PFK-1 could aid in
the treatment of obesity, diabetes and metabolic syndrome. In addition, PFK-1 is increased
in cancer cells [5] suggesting that PFK-1, as well as the other enzymes involved in
glycolysis, is a potential target for anti-cancer drugs [6]. For instance, inhibition of lactate
dehydrogenase resulted in inhibited cell growth in both lymphoma and pancreatic cancer by
inducing oxidative stress [7]. Glycosylation of PFK-1 with N-acetylglucosamine also plays a
role in cancer cell metabolism [8]. Lastly, PFK-1 is being explored as a possible target for
the treatment of the parasitic disease, African sleeping sickness (trypanosomiasis) [9].
Despite the fact that inhibition of PFK-1 is therapeutically relevant to several areas of
medicine there are very few known PFK-1 inhibitors that are suitable for pharmaceutical
applications. This will likely change now that the first three-dimensional structure of a
mammalian PFK-1 is available [10], which will enable structure-based drug design to be
used for inhibitor development.

NIH-PA Author Manuscript

One reason for the shortage of PFK-1 inhibitors could be the lack of suitable assays to
screen for such inhibitors. Coupled enzyme assays are routinely used to measure PFK-1
activity. For example, the rate of ADP production is determined using pyruvate kinase and
lactate dehydrogenase [1], while production of fructose 1,6-bisphosphate can be coupled to
aldolase, glycerol-3-phosphate-dehydrogenase and triosephosphate isomerase [11]. While
these two assays have proven to be very useful for the study of the allosteric behavior of
PFK-1, they have one major shortcoming when it comes to screening for inhibitors. Both
assays rely on the absorbance of NADH at 340 nm as the basis for detection. This is
problematic for screening molecules that might inhibit PFK-1 since many of those
molecules absorb strongly around 340 nm. Therefore, an assay for PFK-1 that obviates the
spectral interference of potential inhibitors would have wide utility. Additionally, there is
always a possibility that an inhibitor can act on one of the reactions only used for detection
purposes in a coupled enzyme assay.
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Capillary electrophoresis (CE) is a separation technique based on differences in the ratio of
charge to hydrodynamic radius for analytes in a conductive solution and can be used to
analyze enzyme kinetics and inhibition [12; 13]. Most importantly, because CE is an
electrophoretic separation technique, the potential for spectral interference by inhibitors is
greatly reduced. Moreover, CE is also a rapid technique that consumes only a few nL of
sample per measurement, and it can be used to screen for and study enzyme inhibitors [12;
14; 15]. A CE assay was developed recently by Meades et al. to study inhibitors of the
carboxyltransferase component of acetyl CoA carboxylase in cases where the inhibitor
spectrally interfered with a coupled enzyme assay based on NADH absorbance at 340 nm
[16]. Here we report the development of a CE assay for PFK-1 and show that the assay can
detect inhibition of PFK-1 activity with known inhibitors.

MATERIALS AND METHODS
Chemicals
Adenosine 5′-triphosphate, adenosine-5′-diphosphate, fructose-6-phosphate, sodium dodecyl
sulfate (SDS), aurintricarboxylic acid (ATA) and palmitoyl coenzyme A (PCoA) were
obtained from Sigma (St. Louis, MO). Tris(hydroxymethyl)aminomethane hydrochloride
(Tris-HCl) was obtained from Promega (Madison, WI, USA). Magnesium chloride was
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from Fisher Scientific (Pittsburgh, PA). All structures are shown in Supplementary Material
(Figure S1).
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Preparation of PFK-1
The rabbit muscle PFK-1 used in these experiments was expressed and purified as described
by Banaszak et al. [10]. The final purified enzyme was suspended in a 50.0 mM solution of
Tris at pH 8.2. The pH of the Tris buffer used to suspend the enzyme was adjusted to 8.2 by
addition of concentrated phosphoric acid. Small aliquots were made and stored at 4 °C.
Using a Bradford assay [17], the final concentration of the PFK-1 was determined to be 0.5
mg/mL.
Capillary Electrophoresis
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A simple laboratory-constructed CE instrument was used for all experiments and is similar
to instruments described previously [18]. Fused-silica capillary (50-μm i.d., 360-μm o.d.)
was purchased from Polymicro (Phoenix, AZ) and cut to 60.0 cm. The polyimide coating
was burned (~1 cm) to make a detection window at 40.0 cm using The Window Maker™
(MicroSolv Technology Corp.; Eatontown, NJ). The electrophoretic potential was applied
with a Spellman CZE 1000R high voltage power supply (Hauppauge, NY). A potential of
25.0 kV (417 V/cm) was used for all experiments. All injections were electrokinetic (3.0 s at
25.0 kV).
Absorbance detection was performed at 260 nm using an Acutect 500 UV/Vis detector
(Scientific Systems; State College, PA) with an on-column capillary cell. A computer
program was written in LabView (Version 7.1, National Instruments) and used for data
acquisition at 100 Hz. Data were analyzed using OriginLab 7.5 (Northampton, MA). All
separation buffers used were prepared to contain 15.0 mM Tris-HCl and 30.0 mM SDS. The
pH was adjusted to 8.00 with 1.0 M KOH. The sample buffer used for separation
development was the same as the enzyme assay buffer described below except that no
PFK-1 was added to the solution. All solutions used for CE experiments were prepared with
ultrapure water (>18 M Ω/cm) obtained from a Modulab water purification system (U.S.
Filter; Palm Desert, CA). All buffers used for CE were filtered using a 0.2 μm nylon
membrane filter prior to use (Whatman; Hillsboro, OR).
Enzyme assays
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Capillary Electrophoresis Assay—The sample buffer used for CE enzyme assays was
based on 15.0 mM Tris-HCl at pH 8.00, and did not contain SDS. The sample buffer also
contained 5.0 mM MgCl2, 1.00 mM ATP and 1.00 mM F6P. To initiate the reaction, 5.0 μL
of 0.5 mg/mL PFK-1 was added to give a final concentration of 5×10−3 mg/mL (typically)
in a total sample volume of 500 μL. All reactions were performed in 600 μL polypropylene
microcentrifuge tubes. For inhibition studies with ATA, the ATA was first suspended in
water, and then KOH was added to a final concentration of 0.02 M. The pH of the solution
after KOH addition was 8.0. When performing the PFK-1 assay with ATA, the ATA was
added to the reaction mixture, and then PFK-1 was added to initiate the reaction.
The capillary was conditioned between each run by successively injecting 0.5 M NaOH,
ultrapure water, then the separation buffer for 5 min each. The Tris-HCl, SDS and
magnesium chloride buffer was then placed into both the inlet and outlet vials. To ensure a
stable current in the capillary and a stable baseline in the electropherogram, electrophoresis
was performed at 25.0 kV for 5 min with no analyte before injection.
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Data Analysis—The dose dependence of inhibition of PFK-1 by ATA was fitted by
nonlinear regression analysis to Equation 1 to determine the concentration of ATA that
inhibits the enzyme activity by 50%.
(1)

In Equation 1, vi is the enzyme activity at a particular ATA concentration and v0 is the
activity in the absence of ATA. The concentration of ATA is [I], and IC50 is the
concentration of ATA that results in 50% inhibition. Enzyme activity was defined as the
ratio of CE peak areas for Mg-ADP/(Mg-ATP+Mg-ADP).

Results and Discussion
Separation and Detection of Mg-ATP and Mg-ADP
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The overall goal of this study was to develop a simple CE assay with UV absorbance
detection for the reaction catalyzed by phosphofructokinase-1 that directly measures
substrate depletion and product formation. The first step in the development of this assay
was to separate and detect the substrates and products for the PFK-1 catalyzed reaction
(Scheme 1). Fructose 6-phosphate and fructose 1,6-bisphosphate exhibit only weak
absorbance in the ultraviolet and would be difficult to detect without derivatization [19]. In
contrast, both ATP and ADP have a strong absorption band near 260 nm, and analysis of
both molecules by CE has been reported previously [20]. An initial, unsuccessful attempt to
separate 1.0 mM ATP and 1.0 mM ADP for this assay using absorbance detection at 260 nm
is presented in Supplementary Material (Figure S2).
The separation buffer for this assay represents a compromise between ideal conditions for
the PFK-1 catalyzed reaction and optimal conditions for the CE separation. The first
separation buffer used during the development of this assay contained 15.0 mM Tris-HCl
and 30 mM SDS at pH 8.00. It has been reported that addition of SDS improves the
separation of ATP and ADP [20; 21]. Under these conditions (above the SDS critical micelle
concentration), the separation is a micellar enhanced capillary electrokinetic
chromatography (MEKC) separation [22]. The separation buffer did not initially contain
Mg2+ in order to lessen the differences in the ionic strength between the separation buffer
and the sample buffer, which did not contain SDS.
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The sample buffer also contained 15.0 mM Tris-HCl at pH 8.00 as well as 5.0 mM MgCl2.
Normally a higher ionic strength buffer (e.g. 50 mM Tris) would be used for the PFK-1
catalyzed reaction as described by Kemp et al. [23], but the conductivity of such buffers
would result in a large electrophoretic current and excessive Joule heating that would
degrade the separation. Preliminary experiments showed that the PFK-1 catalyzed reaction
was substantially slower without Mg2+ in the sample buffer (data not shown). This is
because the metal nucleotide complex is the actual substrate for PFK-1 as indicated in
Scheme 1 [24; 25], and, therefore, the MgCl2 could not be removed from the sample buffer.
The electropherogram obtained using the initial separation buffer (Figure S2) shows at least
four peaks for a separation of ATP and ADP, and the peak shapes are generally poor. The
relative sizes and exact shapes of these peaks were not reproducible. It was hypothesized
that the unexpectedly large number of peaks was due to the dissociation of complexed MgATP and Mg-ADP when these complexes migrated into the separation buffer, which did not
contain Mg2+. Various control experiments (no Mg2+ in the sample buffer, no SDS in the
separation buffer, ADP alone and ATP alone) were performed and were consistent with this
hypothesis. Removing Mg2+ from the sample buffer was not a satisfactory solution because
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of the resulting slow reaction rate. Ultimately, it was necessary to add 1.00 mM Mg2+ to the
separation buffer in order to prevent the dissociation of Mg-ATP and Mg-ADP complexes
during separation, and obtain electropherograms like that shown in Figure 1. The
electropherogram in Figure 1 has two well-resolved peaks, and the addition of Mg2+ to the
separation buffer dramatically improved the reproducibility of the separation.
The effect of addition of Mg2+ and other divalent ions to the separation buffer has been
explored for nucleotide separations but has not been applied previously to CE enzyme
assays [26; 27]. The Mg-ATP and Mg-ADP peaks are baseline resolved, but they are both
distinctly triangular in shape (Mg-ATP fronted, Mg-ADP tailed). These asymmetric peak
shapes are not unexpected because of the necessary mismatch between the reaction buffer
(sample) and separation buffer [28; 29]. Perfectly matching the reaction buffer and
separation buffer is not possible if SDS is used for the separation. If SDS were added to the
reaction buffer, PFK-1 would be denatured and would not catalyze the reaction.
Experiments with SDS added to standard solutions of ATP and ADP indicated that SDS was
not the primary cause of the assymetric peak shapes. This leaves the difference in Mg2+
concentration between the sample solution (5 mM) and separation buffer (1 mM) as the
most likely cause. An alternative approach to reduce the negative impact of metal binding to
ADP and ADP on the separation is to add EDTA to the separation buffer [30; 31], and this
approach has been used in the development of a CE enzyme assay [32].
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Quantitative analysis of Mg-ADP and Mg-ATP using this separation method was examined
with standard solutions from 10 μM to 5 mM. Calibration curves from 10 μM to 1 mM are
presented in the Supplementary Material (Figure S3). These plots show good linearity with
limits of quantification of 13 μM and 20 μM for Mg-ATP and Mg-ADP, respectively. At
concentrations above 1 mM, the electropherograms began to show more than two peaks for
ATP and ADP, similar to separations without Mg2+ in the separation buffer (Figure S2).
This is not unexpected when the ATP and ADP concentrations exceeded the Mg2+
concentration in the separation buffer. The migration time reproducibility for Mg-ATP and
Mg-ADP (RSD for all injections used to produce the calibration curves) was 3%.
CE Assay for PFK-1
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A series of electropherograms for an assay of rabbit muscle PFK-1 [10] are shown in Figure
2. The electropherogram for injection just before addition of PFK-1 to the reaction solution
(Figure 2A) has one peak for Mg-ATP. Figure 2B shows an electropherogram for an
injection 30 s after the addition of PFK-1 (5×10−3 mg/mL). A small Mg-ADP peak is
apparent at 5.6 min. By 8.0 min after PFK-1 addition, the Mg-ADP peak (Figure 2C) is
much larger than the Mg-ATP peak. The electropherogram at 16.0 min after addition of
PFK-1 (Figure 2D) is almost identical to the electropherogram at 8.0 min, indicating that the
reaction was at equilibrium by 8.0 min. These electropherograms show that CE can be used
to monitor PFK-1 activity based on separation and detection of Mg-ATP and Mg-ADP.
Fructose 6-phosphate and fructose 1,6-biphosphate do not appear in the electropherograms
because they do not absorb significantly at 260 nm.
The time dependence for the PFK-1 catalyzed reaction monitored by CE is shown in Figure
3A. The reaction proceeded at a linear rate up to approximately 8 min and then began to
slow. The ratio, [Mg-ADP]/([Mg-ATP]+[Mg-ADP]), was plotted in Figure 3 rather than just
the Mg-ADP concentration (based on Mg-ADP and Mg-ATP peak areas). This normalizes
the measured Mg-ADP concentration to the total concentration of Mg-ATP and Mg-ADP.
This improves precision by reducing the impact of variability in sample injection and is
possible because both the substrate and product are determined in this assay. The linearity of
ADP production was also examined versus PFK-1 concentration (Figure 3B). The ratio,
[Mg-ADP]/([Mg-ATP]+[Mg-ADP]), was determined after 1.5 min based on the experiment
Anal Biochem. Author manuscript; available in PMC 2015 February 15.

Malina et al.

Page 6

presented in Figure 3A. The activity of PFK-1 was approximately linear from 0.0015–
0.0040 μg/μl.
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Inhibition of PFK-1
The ability of the CE assay to detect inhibition of PFK-1 was demonstrated using a known
inhibitor of the enzyme, aurintricarboxylic acid (ATA) [33]. Aurintricarboxylic acid is a
reversible inhibitor of PFK-1 and was reported to have an IC50 of 0.2 μM for rabbit liver
PFK-1 [33]. Electropherograms presented in Supplemental Material (Figure S4) show the
elution of ATP and ADP before addition of PFK-1 (A) and at 30 s (B), 8 min (C) and 16 min
(D) after addition of PFK-1 with 100 μM ATA present in the reaction buffer. Comparison
with the electropherograms at the same reaction times in Figure 2 clearly shows strong
inhibition by 100 μM ATA.
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A dose response curve for ATA inhibition of PFK-1 is shown in Figure 4. Measurements
were made at 1.5 min after addition of PFK-1 (2.25×10−3 mg/mL). At this reaction time,
each experiment required 10 min leading to a sample throughput of 6 hr−1. The data were
plotted as the ratio of [Mg-ADP]/([Mg-ATP]+[Mg-ADP]) for the inhibited/uninhibited
reaction (vi/v0) versus the log of the ATA concentration. After fitting the data by non-linear
regression to Equation 1, the IC50 was determined to be 3.92 ± 0.35 μM. This value is higher
than the IC50 reported by McCune et al. [33]. The rabbit muscle isozyme was used in the
work presented in this paper, while McCune et al. used the rabbit liver isozyme [33].
Moreover, the value reported by McCune et al. [33] was measured at pH 7.3, while the
current study was conducted at pH 8.0. Considering that ATA has three carboxyl groups, it
is likely that binding of the inhibitor to PFK-1 involves ionic interactions and would be pH
dependent. Finally, the IC50 value measured by the CE assay is a direct determination of the
effect of the inhibitor on PFK-1 based on measurement of both Mg-ATP and Mg-ADP and
is uncomplicated by potential interactions of the inhibitor with the coupling enzymes
utilized by McCune et al [33]. The results for ATA (Figure 4) show that the CE assay can
produce excellent quantitative results for inhibition studies.
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One of the end products of fatty acid biosynthesis, palmitoyl-CoA (PCoA), was recently
reported to reversibly inhibit PFK-1 [34]. Electropherograms for the inhibition of PFK-1 by
5.0 μM PCoA are presented in Supplemental Material (Figure S5). As was the case for
ATA, inhibition of PFK-1 is evident based on comparison of the electropherograms in
Figure S5 to those in Figure 2. Attempts to determine an IC50 value like that for ATA
(Figure 4) were unsuccessful due to poor reproducibility for the PCoA inhibition
experiments. This is most likely due to the low solubility of PCoA in the presence of Mg2+,
which has been reported in the literature [35] and observed in the experiments presented
here. Unfortunately, Mg2+ cannot be removed from the assay because PFK-1 activity
depends on its presence.

CONCLUSIONS
A simple and effective capillary electrophoretic assay for studying PFK-1 activity and
inhibition has been developed. Compared to other common assays for this enzyme, the CE
assay does not rely on coupling of the enzyme-catalyzed reaction to a second reaction for
detection. This reduces the possibility of false positive results in studies of enzyme
inhibition. In addition, the CE separation reduces the possibility of spectral interference by
an inhibitor or biological samples [16].

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Electropherogram for the injection of 1.0 mM ATP and 1.0 mM ADP with absorbance
detection at 260 nm. The sample was injected electrokinetically for 3.0 s at 25.0 kV (417 V/
cm). The separation buffer was 15.0 mM Tris-HCl at pH 8.00 with 30.0 mM SDS and 1.0
mM Mg2+. The sample solution also contained 5.0 mM Mg2+ to mimic conditions required
for the PFK-1 assay, but it did not contain SDS. The separation potential was 25.0 kV (417
V/cm), and the electrophoretic current was 25 μA.
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Figure 2.

Electropherograms for the PFK-1 assay. The separation conditions are the same as those
used in Figure 1. The reaction/sample buffer was the same as that used in Figure 1 except
for the addition of PFK-1 and 1.0 mM fructose 6-phosphate. A, Electropherogram for the
reaction mixture just before addition of PFK-1. B, Electropherogram 30 s after the addition
of PFK-1 (5×10−3 mg/mL). C, Electropherogram 8.0 min after the addition of PFK-1. D,
Electropherogram 16.0 min after the addition of PFK-1. The electropherograms for B–D
were artificially offset for ease of viewing.

NIH-PA Author Manuscript
Anal Biochem. Author manuscript; available in PMC 2015 February 15.

Malina et al.

Page 11

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 3.

A, Production of Mg-ADP (reaction rate) for the reaction catalyzed by PFK-1 for reaction
times from 0 to 20.5 min. As explained in the text, peak areas were used to determine the
plotted ratio Mg-ADP/(Mg-ATP+Mg-ADP). All experimental conditions are the same as in
Figure 2 except that the PFK-1 concentration was 2.7×10−3 mg/mL. B, Production of MgADP (reaction rate) versus PFK-1 concentration. The Mg-ADP/(Mg-ATP+Mg-ADP) ratio
was measured at a reaction time of 1.5 min. Error bars represent the standard deviation for 3
measurements.
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Figure 4.

The dose dependence of PFK-1 inhibition by ATA. The Mg-ADP/(Mg-ATP+Mg-ADP)
ratio was measured at 1.5 min using 2.25×10−3 mg/mL of PFK-1 as function of increasing
ATA concentration from 1 nM to 100 μM and divided by the value with no ATA to
determine vi/v0. The plotted points represent the average for three experiments, and the line
represents the best fit of the data to Equation 1.
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